A. Douros

First name
A.
Last name
Douros
Douros, A., Lix, L. M., Fralick, M., Dell'Aniello, S., Shah, B. R., Ronksley, P. E., et al. (2020). Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study. Ann Intern Med, 173, 417-425. http://doi.org/10.7326/m20-0289
View
Dimakos, J., Cui, Y., Platt, R. W., Renoux, C., Filion, K. B., & Douros, A. (2023). Pharmacologic heterogeneity and risk of severe hypoglycemia with concomitant use of sulfonylureas and DPP-4 inhibitors: population-based cohort study. Clin Pharmacol Ther. http://doi.org/10.1002/cpt.2975
View
Islam, N., Reynier, P., Douros, A., H. Y. Yu, O., & Filion, K. B. (2023). Sulfonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: a population-based cohort study. Diabetes Obes Metab. http://doi.org/10.1111/dom.15000
View
Douros, A., Ante, Z., Suissa, S., & Brassard, P. (2022). Common vaccines and the risk of incident dementia: a population-based cohort study. J Infect Dis. http://doi.org/10.1093/infdis/jiac484
View
Dimakos, J., Cui, Y., Platt, R. W., Renoux, C., Filion, K. B., & Douros, A. (2022). Concomitant Use of Sulfonylureas and β-Blockers and the Risk of Severe Hypoglycemia Among Patients With Type 2 Diabetes: A Population-Based Cohort Study. Diabetes Care. http://doi.org/10.2337/dc22-1584
View
Suissa, K., Schneeweiss, S., Douros, A., Yin, H., Patorno, E., & Azoulay, L. (2022). Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes. Diabetes Res Clin Pract, 192, 110094. http://doi.org/10.1016/j.diabres.2022.110094
View
Ayele, H. T., Douros, A., & Filion, K. B. (2022). 5-α reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population-based cohort study. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.15317
View
Douros, A., Yin, H., H. Y. Yu, O., Filion, K. B., Azoulay, L., & Suissa, S. (2017). Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events. Diabetes Care. http://doi.org/10.2337/dc17-0595
View
Douros, A., Dell'Aniello, S., H. Y. Yu, O., Filion, K. B., Azoulay, L., & Suissa, S. (2018). Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. Bmj. http://doi.org/10.1136/bmj.k2693
View
Douros, A., Abrahami, D., Yin, H., H. Y. Yu, O., Renoux, C., Hudson, M., & Azoulay, L. (2018). Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes. Epidemiology. http://doi.org/10.1097/ede.0000000000000891
View